Study of Cadmium Complexes of Amino Acids at their Isoionic Points : Cd(II)-Amino Acid & Cd(II)- Thiourea- Amino Acid Systems

208-20

Thermodynamics of complex formation of rare earth metal ions with schiff bases in mixed solvent media

1014-1015Proton-ligand stability constants of N-phenyl-2-hydroxy- 5- chioroacetophenoneimine(I) and N-ɑ-naphthyl- 2-hydroxy- 5-chioroacetophenoneimine(II) and metal-ligand stability constants of their complexes with La(III), Ce(III), Pr(III), Nd(III), Sm(III), Gd(III), Tb(I1I), Dy(III) and Yb(III) have been determined at 25°, 35° and 50°C (± 0.02°C) and and μ =0.l M(NaClO4) in 60% ethanol-water medium. The thermodynamic parameters for the formation of 1:1 and 1:2 complexes have been calculated. The metal complexes of the ligand(I) are observed to be enthalpy- and entropy-stabilized. However, the positive values of enthalpy and entropy changes in the case of the 1:2 complexes of ligand(II) show the predominance of the entropy effect

Design of a high-power compact SRF linac for industrial applications of e-beam irradiation

Fermilab has developed a novel concept for an industrial electron linac using Nb3Sn coating technology and conduction cooling. These conduction-cooled linacs can generate electron beam energies up to 10 MeV in continuous-wave operation and reach higher power (>=1 MW) by combing several modules. Compact and light enough to mount on mobile platforms, our machine is anticipated to enable new in-situ environmental remediation applications such as waste-water treatment for urban areas, X-ray medical device sterilization, and innovative pavement applications. We highlight a few aspects of a 1 MW design of such a machine in this paper. A detailed plan is in Dhuley et al. (2022) Phys. Rev. Accel. Beams 25, 041601.Comment: arXiv admin note: substantial text overlap with arXiv:2112.0923

Polarographic Study of Mixed Ligand Complexes: Cd(II)-Oxalate-Phthalate System

63-6

Warm Compressor system Overview and status of the PIP-II cryogenic system

The Proton Improvement Plan-II (PIP-II) is a major upgrade to the Fermilab accelerator complex, featuring a new 800-MeV Superconducting Radio-Frequency (SRF) linear accelerator (Linac) powering the accelerator complex to provide the world's most intense high-energy neutrino beam. The PIP-II Linac consists of 23 SRF cryomodules operating at 2 K, 5 K, and 40 K temperature levels supplied by a single helium cryoplant providing 2.5 kW of cooling capacity at 2.0 K. The PIP-II cryogenic system consists of two major systems: a helium cryogenic plant and a cryogenic distribution system. The cryogenic plant includes a refrigerator cold box, a warm compressor system, and helium storage, recovery, and purification systems. The cryogenic distribution system includes a distribution box, intermediate transfer line, and a tunnel transfer line consisting of modular bayonet cans which supply and return cryogens to the cryomodules. A turnaround can is located at the end of the Linac to turnaround cryogenic flows. This paper describes the layout, design, and current status of the PIP-II cryogenic system.Comment: 2023 Cryogenic Engineering Conference and International Cryogenic Materials Conference (CEC/ICMC

High catechin concentrations detected in Withania somnifera (ashwagandha) by high performance liquid chromatography analysis

<p>Abstract</p> <p>Background</p> <p><it>Withania somnifera </it>is an important medicinal plant traditionally used in the treatment of many diseases. The present study was carried out to characterize the phenolic acids, flavonoids and 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) scavenging activities in methanolic extracts of <it>W. somnifera </it>fruits, roots and leaves (WSFEt, WSREt and WSLEt).</p> <p>Methods</p> <p>WSFEt, WSREt and WSLEt was prepared by using 80% aqueous methanol and total polyphenols, flavonoids as well as DPPH radical scavenging activities were determined by spectrophotometric methods and phenolic acid profiles were determined by HPLC methods.</p> <p>Results</p> <p>High concentrations of both phenolics and flavonoids were detected in all parts of the plant with the former ranging between 17.80 ± 5.80 and 32.58 ± 3.16 mg/g (dry weight) and the latter ranging between 15.49 ± 1.02 and 31.58 ± 5.07 mg/g. All of the three different plant parts showed strong DPPH radical scavenging activities (59.16 ± 1.20 to 91.84 ± 0.38%). Eight polyphenols (gallic, syringic, benzoic, p-coumaric and vanillic acids as well as catechin, kaempferol and naringenin) have been identified by HPLC in parts of the plant as well. Among all the polyphenols, catechin was detected in the highest concentration (13.01 ± 8.93 to 30.61 ± 11.41 mg/g).</p> <p>Conclusion</p> <p>The results indicating that <it>W. somnifera </it>is a plant with strong therapeutic properties thus further supporting its traditional claims. All major parts of <it>W. somnifera </it>such as the roots, fruits and leaves provide potential benefits for human health because of its high content of polyphenols and antioxidant activities with the leaves containing the highest amounts of polyphenols specially catechin with strong antioxidant properties.</p

Naturopathic Care for Anxiety: A Randomized Controlled Trial ISRCTN78958974

BACKGROUND: Anxiety is a serious personal health condition and represents a substantial burden to overall quality of life. Additionally anxiety disorders represent a significant cost to the health care system as well as employers through benefits coverage and days missed due to incapacity. This study sought to explore the effectiveness of naturopathic care on anxiety symptoms using a randomized trial. METHODS: Employees with moderate to severe anxiety of longer than 6 weeks duration were randomized based on age and gender to receive naturopathic care (NC) (n = 41) or standardized psychotherapy intervention (PT) (n = 40) over a period of 12 weeks. Blinding of investigators and participants during randomization and allocation was maintained. Participants in the NC group received dietary counseling, deep breathing relaxation techniques, a standard multi-vitamin, and the herbal medicine, ashwagandha (Withania somnifera) (300 mg b.i.d. standardized to 1.5% with anolides, prepared from root). The PT intervention received psychotherapy, and matched deep breathing relaxation techniques, and placebo. The primary outcome measure was the Beck Anxiety Inventory (BAI) and secondary outcome measures included the Short Form 36 (SF-36), Fatigue Symptom Inventory (FSI), and Measure Yourself Medical Outcomes Profile (MY-MOP) to measure anxiety, mental health, and quality of life respectively. Participants were blinded to the placebo-controlled intervention. RESULTS: Seventy-five participants (93%) were followed for 8 or more weeks on the trial. Final BAI scores decreased by 56.5% (p<0.0001) in the NC group and 30.5% (p<0.0001) in the PT group. BAI group scores were significantly decreased in the NC group compared to PT group (p = 0.003). Significant differences between groups were also observed in mental health, concentration, fatigue, social functioning, vitality, and overall quality of life with the NC group exhibiting greater clinical benefit. No serious adverse reactions were observed in either group. RELEVANCE: Many patients seek alternatives and/or complementary care to conventional anxiety treatments. To date, no study has evaluated the potential of a naturopathic treatment protocol to effectively treat anxiety. Knowledge of the efficacy, safety or risk of natural health products, and naturopathic treatments is important for physicians and the public in order to make informed decisions. INTERPRETATION: Both NC and PT led to significant improvements in patients' anxiety. Group comparison demonstrated a significant decrease in anxiety levels in the NC group over the PT group. Significant improvements in secondary quality of life measures were also observed in the NC group as compared to PT. The whole system of naturopathic care for anxiety needs to be investigated further including a closer examination of the individual components within the context of their additive effect. TRIAL REGISTRATION: Controlled-Trials.com ISRCTN78958974